Mapakna Lp

Nifedipine, the active ingredient in Mapakna Lp, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower high blood pressure, relieve chest pain from chronic stable angina, and improve blood flow in Raynaud's phenomenon, primarily in adult patients.

GNH USA supplies Mapakna Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Nifedipine, a calcium channel blocker, is used to manage vascular and cardiac conditions by relaxing smooth muscle.

Hypertension: Reduces systemic vascular resistance, lowering blood pressure. Chronic stable angina: Improves myocardial oxygen supply by dilating coronary arteries, decreasing chest pain episodes. Raynaud's phenomenon: Enhances peripheral blood flow, reducing frequency and severity of vasospastic attacks.

Nifedipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, especially after the first dose. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness: related to blood pressure reduction.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing nifedipine, clinicians should consider several safety measures to minimize risk. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Discontinuation: avoid abrupt cessation; taper gradually under medical supervision. - Hepatic impairment: use with caution in patients with liver disease due to altered metabolism. - Heart failure: assess severity; use cautiously in decompensated cases. - Elderly patients: start at lower dose and monitor for dizziness or falls. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Nifedipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise nifedipine levels and increase toxicity. - Grapefruit juice: can markedly increase plasma concentration, leading to severe hypotension. - Concurrent potent vasodilators (e.g., nitroglycerin): risk of additive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce nifedipine effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Diuretics: combined use can enhance hypotensive effect, requiring dose adjustment.